BACKGROUND: The efficacy of bupropion hydrochloride sustained release (SR) (Zyban) for smoking cessation has been evaluated in clinical trials that included frequent in-person behavioral counseling, but not in actual practice settings. OBJECTIVE: To determine the differential effectiveness of 2 doses of bupropion SR in combination with behavioral interventions of minimal to moderate intensity in an actual practice setting. DESIGN: Open-label randomized trial, with 1 year of follow-up. SETTING: A large health system (Group Health Cooperative) based in Seattle. PARTICIPANTS: Adult smokers (N = 1524) interested in quitting smoking. INTERVENTIONS: Participants were randomly assigned to receive 1 of 4 combinations of bupropion SR (150 or 300 mg) and behavioral counseling (minimal or moderate intensity). MAIN OUTCOME MEASURES: The primary outcome measure was self-reported point-prevalence 7-day nonsmoking status at 3 and 12 months following the target quit date. Secondary outcomes included adverse and abstinence effects reported since beginning treatment with bupropion SR. RESULTS: At 3 months, a significantly higher rate of nonsmoking was observed among those receiving the larger bupropion SR dose (P=.005). At 12 months, moderate intensity counseling was associated significantly with a higher rate of nonsmoking (P=.001). At 3 months, the higher dose was associated with a significantly increased frequency of self-reported symptoms such as difficulty sleeping (P=.02), difficulty concentrating (P=.02), shakiness/tremor (P=.002), and gastrointestinal problems (P=.005)and a decreased frequency of reported desire to smoke (P=.001). CONCLUSIONS: In this actual practice setting, the combination of bupropion SR and minimal or moderate counseling was associated with 1-year quit rates of 23.6% to 33.2%. This suggests that existing health care systems can substantially decrease tobacco use rates among their enrollees if they provide these modest interventions.
RCT Entities:
BACKGROUND: The efficacy of bupropion hydrochloride sustained release (SR) (Zyban) for smoking cessation has been evaluated in clinical trials that included frequent in-person behavioral counseling, but not in actual practice settings. OBJECTIVE: To determine the differential effectiveness of 2 doses of bupropion SR in combination with behavioral interventions of minimal to moderate intensity in an actual practice setting. DESIGN: Open-label randomized trial, with 1 year of follow-up. SETTING: A large health system (Group Health Cooperative) based in Seattle. PARTICIPANTS: Adult smokers (N = 1524) interested in quitting smoking. INTERVENTIONS:Participants were randomly assigned to receive 1 of 4 combinations of bupropion SR (150 or 300 mg) and behavioral counseling (minimal or moderate intensity). MAIN OUTCOME MEASURES: The primary outcome measure was self-reported point-prevalence 7-day nonsmoking status at 3 and 12 months following the target quit date. Secondary outcomes included adverse and abstinence effects reported since beginning treatment with bupropion SR. RESULTS: At 3 months, a significantly higher rate of nonsmoking was observed among those receiving the larger bupropion SR dose (P=.005). At 12 months, moderate intensity counseling was associated significantly with a higher rate of nonsmoking (P=.001). At 3 months, the higher dose was associated with a significantly increased frequency of self-reported symptoms such as difficulty sleeping (P=.02), difficulty concentrating (P=.02), shakiness/tremor (P=.002), and gastrointestinal problems (P=.005)and a decreased frequency of reported desire to smoke (P=.001). CONCLUSIONS: In this actual practice setting, the combination of bupropion SR and minimal or moderate counseling was associated with 1-year quit rates of 23.6% to 33.2%. This suggests that existing health care systems can substantially decrease tobacco use rates among their enrollees if they provide these modest interventions.
Authors: David T Levy; Patricia L Mabry; Amanda L Graham; C Tracy Orleans; David B Abrams Journal: Am J Public Health Date: 2010-05-13 Impact factor: 9.308
Authors: Jack F Hollis; Timothy A McAfee; Jeffrey L Fellows; Susan M Zbikowski; Michael Stark; Karen Riedlinger Journal: Tob Control Date: 2007-12 Impact factor: 7.552
Authors: Benjamin A Toll; Stephanie S O'Malley; Nicole A Katulak; Ran Wu; Joel A Dubin; Amy Latimer; Boris Meandzija; Tony P George; Peter Jatlow; Judith L Cooney; Peter Salovey Journal: Psychol Addict Behav Date: 2007-12
Authors: Stevens S Smith; Danielle E McCarthy; Sandra J Japuntich; Bruce Christiansen; Megan E Piper; Douglas E Jorenby; David L Fraser; Michael C Fiore; Timothy B Baker; Thomas C Jackson Journal: Arch Intern Med Date: 2009-12-14
Authors: Jonathan B Bricker; Terry Bush; Susan M Zbikowski; Laina D Mercer; Jaimee L Heffner Journal: Nicotine Tob Res Date: 2014-06-16 Impact factor: 4.244